Alecensa (alectinib) demonstrated a 22% reduction in the risk of death compared with Xalkori (crizotinib) in the frontline ...
Although several novel agents are on the horizon, including next-generation tyrosine kinase inhibitors for tertiary mutations ...
October 27, 2025 - The BrightSpark Group, a Savannah-based training and development company, officially launched SPARK, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback